Latest stories on NBIX
Neurocrine presents new analysis establishing benchmark in dyskinesia treatment
The Fly63 · neutralproduct/pr
Where Will Neurocrine Biosciences Be in 5 Years?
The Motley Fool63 · neutralgeneral
Neurocrine begins Phase 2 study of NBI-‘567 in adults with Alzheimer’s disease
The Fly58 · neutralproduct/pr
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
StockTitan58 · neutralproduct/pr
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
PR Newswire56 · neutralproduct/pr
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook
Investing.com Analyst Ratings56 · neutralanalyst
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Yahoo Top50 · neutralgeneral
NBIX Sets Nov. 2 Timeline for Q3 2026 Results: Release at 4:00 p.m. ET, Call at 4:30 p.m. ET
MarketChameleon50 · neutralgeneral
NBIX Sets Nov. 2 Timeline for Q3 2026 Results, With Webcast Replay Archived for About a Month
October 13, 2026
MarketChameleon50 · neutralearnings
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
PR Newswire50 · neutralgeneral
Neurocrine price target lowered to $150 from $164 at BMO Capital
The Fly34 · bearishanalyst
Neurocrine assumed with a Buy at Guggenheim
The Fly63 · neutralanalyst
Neurocrine price target lowered to $214 from $231 at UBS
The Fly34 · bearishanalyst
NEUROCRINE BIOSCIENCES INC (NBIX) files 8-K
SEC 8-K50 · neutralgeneral
Neurocrine names Eiry Roberts, M.D., as Chief Medical Officer
The Fly56 · neutralgeneral
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
PR Newswire65 · bullishgeneral
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? - qz.com
Quartz63 · neutralproduct/pr
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
Yahoo Top73 · bullishproduct/pr
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Neurocrine price target raised to $183 from $182 at Morgan Stanley
The Fly61 · neutralanalyst
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking Alpha56 · neutralproduct/pr
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral